XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Turner, Joel G., Kashyap, Trinayan, Dawson, Jana L., Gomez, Juan, Bauer, Alexis A., Grant, Steven, Dai, Yun, Shain, Kenneth H., Meads, Mark, Landesman, Yosef, Sullivan, Daniel M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2016
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340237/
https://ncbi.nlm.nih.gov/pubmed/27806331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12969
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk